'Seeds of change' sprout in­to high­er pro­ject­ed re­turn on in­vest­ments for the bio­phar­ma in­dus­try, ac­cord­ing to De­loitte

Since 2010, De­loitte has been track­ing the re­turn on in­vest­ment that a hand­ful of top bio­phar­ma com­pa­nies might ex­pect to see from their late-stage as­sets. Last year, the com­pa­ny not­ed “seeds of change” fol­low­ing a six-year de­cline in av­er­age in­ter­nal rate of re­turns.

De­loitte’s lat­est re­port in­di­cates the trend has con­tin­ued this year, as pro­ject­ed R&D re­turns have risen from 2.7% to 7%, the largest an­nu­al in­crease since the study be­gan in 2010.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.